Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate in ALS patients the regulatory T cell early response to
two low-doses of IL-2 at 1 and 2 MIU per day after one course of 5 consecutive days
comparatively to placebo.